Clinical trials: Depressive Episodes
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depression, Depressive Episodes
Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health
The purpose of this randomized multiple-site clinical study is to determine whether a revised CATCH-IT (Internet-based depression prevention program) is more effective than a general health education Internet intervention (Health…
- Trial name
- CATCH-IT (NCT01893749)
- Testing
- CATCH-IT
- Where
- 7 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Benjamin Van Voorhees, MD, MPH
Depressive Episode
Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression
The aim of the present study will be to observe the changes in the NTs like Nerve growth factor, Neurotrophin-3, and Neurotrophin-4 in patients with depression and study the effect of various antidepressants like Sertraline…
- Trial name
- NCT03126188
- Testing
- Sertraline, Dosulepin, Venlafaxine
- Where
- India
- Volunteers
- 105 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Depression
Treating Depression With Transcranial Direct Current Stimulation (tDCS)
The purpose of this study is to see if transcranial direct current stimulation may improve the symptoms of depression.
- Trial name
- NCT00481988
- Testing
- transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Psychotic Disorders, Autism Spectrum Disorder
EEG Microstates Across At-Risk Mental States
The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6).
- Conditions
- Psychotic Disorders, Autism Spectrum Disorder, Major Depressive Disorder, Schizophrenia
- Trial name
- DEMETER (NCT06045897)
- Testing
- EEG 64 channels, Polysomnography 19 electrodes, Light hypnosis
- Where
- France
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Bipolar Disorder I, Bipolar Disorder II
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
- Trial name
- NCT03692910
- Testing
- SAGE-217
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Major Depressive Disorder
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode.
- Trial name
- NCT01684163
- Testing
- GLYX-13 5 mg/kg, GLYX-13 10 mg/kg
- Where
- 26 sites in United States
- Volunteers
- 369 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Mental Disorders
Combination Of PAXIL Tablet And Benzodiazepines
This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive episodes who have received…
- Trial name
- NCT00259883
- Testing
- paroxetine
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Depression, Depressive Disorder, Treatment-Resistant
OSU6162 as add-on in SSRI/SNRI-resistant Depression
This is a randomised, placebo-controlled, parallel-group trial comparing OSU6162 at flexible dosage with placebo as add-on to treatment with an SSRI/SNRI in patients with depression that have not responded to treatment with an…
- Conditions
- Depression, Depressive Disorder, Treatment-Resistant, Depressive Disorder, Depressive Episode
- Trial name
- ODEN (NCT05641623)
- Testing
- OSU6162
- Where
- 4 sites in Sweden
- Volunteers
- 180 people
- Sponsor
- Göteborg University
Bipolar Depression
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B.
- Trial name
- NCT02600494
- Testing
- ITI-007 (Lumateperone)
- Where
- 55 sites in United States
- Volunteers
- 554 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Episode
The RAFT ECT Study
Severe depression is devastating for those affected and is often associated with significant risk of suicide. Electroconvulsive therapy (ECT) is a highly effective acute treatment for severe depression, but its use and…
- Trial name
- RAFT-ECT (NCT05402657)
- Testing
- Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
- Where
- 7 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- The George Institute
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Bipolar Disorder Depression
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
The goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment(s) can improve clinical symptoms of depression and to learn about potential effects on brain chemistry that may correlate with…
- Trial name
- NCT06869187
- Testing
- ABX-002
- Where
- 14 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Autobahn Therapeutics, Inc.
Depression, Depression Moderate
Paramedical Tele-education on Moderate Depressive Episodes
Considering that one out of five people may experience depression during the course of their life, and that compliance to anti-depression medication is often not optimal.
- Trial name
- TE-DSP (NCT06014125)
- Testing
- psychoeducative program
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Toulouse
Major Depressive Disorder
A Study of Aripiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT00105196
- Testing
- Aripiprazole+ ADT
- Where
- 34 sites in United States
- Volunteers
- 349 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autism Spectrum Disorder, Depression
Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)
Depression is a common complication of Autism Spectrum Disorder (ASD): it is four times more prevalent in people with ASD than in the general population.
- Conditions
- Autism Spectrum Disorder, Depression, Major Depressive Episode (MDE)
- Trial name
- DEPASS'R (NCT07258914)
- Testing
- rTMS, rTMS treatment with intermittent Theta Burst (ITBS)
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospital Center Guillaume Régnier
Depressive Episode, Electroconvulsive Therapy
Electroconvulsive Treatment Followed by Cognitive Control Training
Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high.
- Conditions
- Depressive Episode, Electroconvulsive Therapy, Cognitive Remediation
- Trial name
- ECT-CCT (NCT04383509)
- Testing
- Cognitive Control Training, Active Control
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- University Ghent
Major Depressive Disorder
Switching From SSRI to Desvenlafaxine on Cognitive Functioning
Given the importance of cognitive function on depressed patients' treatment outcome and return to premorbid functioning, the effect of antidepressant drugs on cognition has become of primary concern.
- Trial name
- NCT03432221
- Testing
- Desvenlafaxine
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
Mood Disorder (Depressive Episodes)
Effect of Music Therapy in Depressive Symptoms of Mood Disorder（EMTDSMD）
Depressive symptom is a common symptom that can be present in various psychiatric conditions, including depression and bipolar disorder.
- Trial name
- NCT05879809
- Testing
- The mini apps named "SOUL GYM" on the Wechat
- Volunteers
- 150 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
- Trial name
- PHOENIX (NCT00252330)
- Testing
- SR58611A
- Where
- 2 sites in United States, Canada
- Volunteers
- 476 people
- Sponsor
- Sanofi